Summary: Immuno-imaging is a novel technique that utilizes labeled antibodies or engineered antibody fragments as a means for disease diagnosis and assessment of treatment planning/monitoring. Monoclonal antibodies (mAbs) have been used to target specific lesion sites due to their high affinity and specificity to specific biomarkers. A common strategy to improve drug delivery is the use of mAbs in conjunction with multi-modality imaging, utilizing both PET/SPECT and near infrared optical imaging. This combination of nuclear and non-ionizing methodologies allows for researchers to demonstrate proof of concept using radionuclide-based modalities, and then switch to a non-ionizing optical modality to perform longitudinal studies, thereby saving on cost per experiment while still being able to investigate efficacy from a longitudinal standpoint.
See the full article here